Revvity To Hold Earnings Call on Monday, April 29, 2024
Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2024 financial results prior to market open on Monday, April 29, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.
To access the call, a live audio webcast will be available via this registration form or on the Investors section of the Company's website.
About Revvity
At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.
The report "Anti-Migrating Agent Market by Type (Non-ionic, Anionic, Cationic, Amphoteric), Grades (Technical, Food, Pharmaceutical), Application, Chemistry (Organic, Inorganic), End-Use Industry (Textile, Plastics, Paper), and Region - Global...
Gupshup, the world's leading Conversation Cloud, in collaboration with Meta, the Sudan Medical Specialization Board and non-profit Shabaka today announced the launch of a telemedicine chatbot providing healthcare access for Sudanese refugees in...
The revenue in June for Zinzino's sales markets increased by 13% and amounted to SEK 148.5 (131.4) million. Faun Pharma's external sales decreased and amounted to SEK 5.8 (8.5) million. Overall, the Group increased revenues by 10% to SEK 154.3...
The global Specialty Enzymes Market size is estimated to be valued at USD 6.1 billion in 2024 and is projected to reach USD 9.2 billion by 2029, recording a CAGR of 8.5% from 2024 to 2029 according to a report published by MarketsandMarketstm. The...
Kvantify, a leading quantum software start-up, has announced the successful closure of a EUR 10 million seed round. This funding will enable Kvantify to strengthen its position as a global leader in quantum computing, with an initial focus on...
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Cytotoxic Drugs and HPAPI Manufacturing Market- (Type of Product (HPAPI and highly potent finished dosage form), Company Size (Small, Mid-sized, Large,...
